id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_xqiqacwx5jbdrkbdihozui7eym	N. M. Hahn	Hoosier Oncology Group Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis	2006	7	.pdf	application/pdf	4890	584	56	prostate cancer (HRPC) patients and to examine the prognostic role of polymorphisms in host Patients randomized to the DV arm received i.v. vinorelbine over 6 to Pharmacogenetic polymorphism frequencies were analyzed in relation to clinical benefit, PSA response, and overall survival Five of 32 (15.6%) patients (95% CI, 5.0-32.0) experienced grade 3 or 4 toxicity in the DV arm. docetaxel in the treatment of HRPC patients, objective response combined with docetaxel in prostate cancer cell line experiments was a basis for its inclusion in this trial (27). The total number of patients experiencing clinically significant toxicity with the combination of vinorelbine and docetaxel Pharmacogenetic polymorphism analysis in patients surviving >15 months Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase Docetaxel,Vinorelbine, and Estramustine Phase II Study Docetaxel,Vinorelbine, and Estramustine Phase II Study Docetaxel,Vinorelbine, and Estramustine Phase II Study vinorelbine andlow-dose docetaxel inchemotherapynaI«ve patients with hormone-refractory prostate cancer.	./cache/work_xqiqacwx5jbdrkbdihozui7eym.pdf	./txt/work_xqiqacwx5jbdrkbdihozui7eym.txt